Table 2 Clinical characteristics of patients with primary Sjögren’s syndrome and nonspecific dryness syndrome
Primary Sjögren’s syndrome (AECG) n = 65 | Nonspecific dryness syndrome n = 132 | *p-value | |
|---|---|---|---|
Age (years) | 49.6 ± 12 | 45.8 ± 12.9 | 0.02 |
Gender (Women) | 65 (98.5%) | 123 (94.6%) | 0.36 |
Oral symptoms | 60 (90.9%) | 95 (85.6%) | 0.42 |
Ocular symptoms | 61 (92.4%) | 90 (81.1%) | 0.07 |
Salivary flow (<0.1 ml/min) | 53 (80.3%) | 51 (46.4%) | 0.00 |
Schirmer (≤5 mm) | 42 (70.0%) | 50 (56.2%) | 0.13 |
Focal Sialoadenitis (focus score ≥ 1) | 59 (89.4%) | 7 (5.4%) | 0.00 |
Anti-SSA and/or anti-SSB | 21 (32.3%) | 6 (6.2%) | 0.00 |
Rheumatoid Factor (látex) | 14 (25.9%) | 22 (21.0%) | 0.62 |
ANA | 39 (66.1%) | 44 (40.0%) | 0.00 |
Fibromyalgia | 41 (63%) | 57 (43.6%) | 0.01 |
Hypertension | 26 (39.4%) | 38 (29.2%) | 0.20 |
Dyslipidemia | 10 (15.2%) | 12 (9.2%) | 0.31 |
Diabetes Mellitus | 4 (6.1%) | 13 (10.0%) | 0.52 |
Depression | 8 (12.1%) | 12 (9.2%) | 0.70 |
Hyperthyroidism, Graves Disease | 8 (12.1%) | 9 (6.9%) | 0.34 |
Osteoporosis/Osteopenia | 8 (12.1%) | 9 (6.9%) | 0.34 |
Osteoarthritis | 20 (30.3%) | 28 (21.5%) | 0.24 |
Neoplasia | 5 (7.6%) | 2 (1.5%) | 0.08 |